Smarter radiation aims to outsmart pancreatic cancer

NCT ID NCT04699539

Completed Disease control Sponsor: Changhai Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested whether a new way of targeting radiation (based on where the cancer usually comes back) works better than the standard method for locally advanced pancreatic cancer. 96 patients received either the new or standard radiation. The study looked at how long patients lived without the cancer growing and overall survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: radiation therapy (stereotactic body radiation therapy, SBRT)
What this could lead to: If successful, this could lead to a more effective way to target radiation for pancreatic cancer, potentially improving survival without increasing side effects.
What could go wrong: This is a small, early-phase trial (96 people) and results may not apply to all patients. The new approach may not improve outcomes and could cause more side effects due to larger radiation fields.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TREATMENT

Contacts and locations

Locations

Changhai hospital

Shanghai, Shanghai Municipality, 200433, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.